Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Monotherapy in First-line Treatment of Advanced Driver Gene-negative NSCLC in Patients Aged ≥70 Years
ChiCTR2600128254Phase 2Not yet recruiting
- Sponsor
- Central Hospital of Guangdong Provincial Nongken
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Central Hospital of Guangdong Provincial Nongken. Primary endpoint: Overall survival rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600128254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128254.